National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Eli Lilly and Company (Lilly) to offer a new funding opportunity seeking proposals to improve patient care and outcomes in lung and thyroid cancers. Multiple factors contribute to the complexity of treating these diseases, including stage and histology, personalization of systemic therapy based on molecular profiles, patient factors, and therapeutic landscape. Please note that this document can also be accessed online at https://www.nccn.org/education-research/nccn-oncology-research-program/orp-main-page.
NCCN views this collaboration with Lilly as clear recognition of the advantages offered to investigators from NCCN member institutions through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.
Proposals must be submitted by 5:00 pm ET on Tuesday, September 28, 2021. Please direct questions regarding this RFP to Nicole Zion at zion@nccn.org with the subject line, “2021 Lilly Quality Project.”
This RFP aims to explore the barriers to biomarker testing from tissue acquisition to treatment initiation which may result in missed or delayed treatment opportunities leading to sub-optimal treatment outcomes. Adherence to the NCCN guidelines for testing in NSCLC and advanced thyroid cancers promotes a standardized approach to biomarker testing across all practice settings in these diseases.
Projects should propose novel ideas to overcoming barriers to biomarker testing in NSCLC and metastatic thyroid cancer. Additionally, proposals that include novel ways to educate patients to be better advocates for themselves through self-empowerment regarding the importance of biomarkerbased treatment initiation are encouraged. Ideal solutions would be able to be disseminated and scaled to encompass both academic and community-based practices throughout the United States.